Oncolytics Biotech Inc. (ONCY)
After hours:
| Previous close | 1.2400 |
| Open | 1.2400 |
| Bid | 1.1500 x 400 |
| Ask | 1.1800 x 200 |
| Day's range | 1.1350 - 1.2500 |
| 52-week range | 0.8800 - 3.3900 |
| Volume | |
| Avg. volume | 315,268 |
| Market cap | 88.241M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3000 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.84 |
Insider MonkeyOncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript May 9, 2024 Oncolytics Biotech Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to Oncolytics Biotech’s First Quarter 2024 Conference Call. [Operator Instructions]. Please be advised […]
PR NewswireOncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced recent operational highlights and financial results for the first quarter ended March 31, 2024. All dollar amounts are expressed in Canadian currency unless otherwise noted.
- PR Newswire
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals. This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq®) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC
